Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) will post its Q314 quarterly earnings results on Thursday, July 31st. Analysts expect Alkermes Plc to post earnings of $0.14 per share and revenue of $146.91 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Alkermes Plc (NASDAQ:ALKS) traded up 1.95% on Wednesday, hitting $45.56. 86,691 shares of the company’s stock traded hands. Alkermes Plc has a one year low of $29.36 and a one year high of $54.25. The stock has a 50-day moving average of $47.90 and a 200-day moving average of $47.15. The company’s market cap is $6.584 billion.

ALKS has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, July 11th. They now have a $50.00 price target on the stock. On the ratings front, analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $49.50.

In other Alkermes Plc news, CFO James M. Frates sold 8,000 shares of the stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $46.50, for a total value of $372,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.